Research Topics
Genomes and GenesSpecies | M C DubinskySummaryAffiliation: Cedars-Sinai Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Special issues in pediatric inflammatory bowel diseaseMarla Dubinsky
Pediatric IBD Center, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
World J Gastroenterol 14:413-20. 2008..This review highlights special considerations in the management of the child with IBD...
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel diseaseMarla C Dubinsky
Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
Gastroenterology 122:904-15. 2002..The objectives of this study were to determine whether dose escalation optimizes both 6-TGN levels and efficacy in patients failing therapy because of subtherapeutic 6-TGN levels and its effect on TPMT...- An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapyM C Dubinsky
Department of Medicine, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
Inflamm Bowel Dis 7:181-9. 2001..This pilot study evaluated the safety, tolerance, and efficacy of 6-TG in the subgroup of Crohn's disease (CD) patients failing to attain adequate disease control with traditional 6-MP/AZA therapy... - IL-23 receptor (IL-23R) gene protects against pediatric Crohn's diseaseMarla C Dubinsky
Department of Pediatrics, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
Inflamm Bowel Dis 13:511-5. 2007..It is unknown whether IL-23R is associated with IBD in children. The aim was to examine the association of IL-23R with susceptibility to IBD in pediatric patients... - Optimizing immunomodulator therapy for inflammatory bowel diseaseMarla C Dubinsky
Pediatric IBD Center, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 1165W, Los Angeles, CA 90048, USA
Curr Gastroenterol Rep 5:506-11. 2003.... - 6-thioguanine can cause serious liver injury in inflammatory bowel disease patientsMarla C Dubinsky
Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8635 West Third Street, Suite 1165W, Los Angeles, California 90048, USA
Gastroenterology 125:298-303. 2003..The aim of this study was to describe the association between 6-TG and NRH in IBD... 
Increased immune reactivity predicts aggressive complicating Crohn's disease in childrenMarla C Dubinsky
Department of Pediatrics, IBD Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 6:1105-11. 2008..The aims of this study were to determine whether immune responses and/or CARD15 variants are associated with complicated disease phenotypes and predict disease progression...- What is the role of serological markers in IBD? Pediatric and adult dataMarla Dubinsky
Pediatric IBD Center, Cedars Sinai Medical Center, David Geffen School of Medicine, Los Angeles, CA 90048, USA
Dig Dis 27:259-68. 2009..This search, however, has taken a very exciting turn in the direction of finding biologic and genetic markers that can assess the natural history and predict the course of individual's disease including response to treatments over time... - Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettesE Esrailian
David Geffen School of Medicine at UCLA, Division of Digestive Diseases, Los Angeles, CA 90095, USA
Aliment Pharmacol Ther 26:1005-18. 2007..When faced with the same set of facts, healthcare providers often make different diagnoses, employ different tests and prescribe disparate therapies... - MAGI2 genetic variation and inflammatory bowel diseaseDermot P B McGovern
Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Inflamm Bowel Dis 15:75-83. 2009..Our aim was to test MAGI2 variants for association with IBD and also their role in determining intermediate hereditary phenotypes defined by antibody production to microbial antigens... - New patients: should children be treated differently?M C Dubinsky
Pediatric IBD Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Colorectal Dis 8:15-9. 2006..A recent case report, involving a 15-year old boy presenting with abdominal pain and bloody diarrhoea, illustrates the difficulty in correctly diagnosing IBD in children and the need for optimizing therapy to achieve treatment success... - A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitisZuri A Murrell
Department of Surgery, Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Dis Colon Rectum 52:872-8. 2009..The aim of this study was to prospectively evaluate the long-term outcome of ileal pouch-anal anastomosis in a closely monitored cohort of patients with ulcerative colitis or indeterminate colitis... - Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitisGil Y Melmed
Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Dis Colon Rectum 51:100-8. 2008..Preoperative predictors for Crohn's disease post-ileal pouch-anal anastomosis have not been prospectively defined... - Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosisPhillip Fleshner
Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 6:561-8. 2008..The aim of this study was to assess associations of preoperative perinuclear antineutrophil cytoplasmic antibody (pANCA) and anti-CBir1 flagellin on AP or CP development... - Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologistsBrennan M R Spiegel
Veteran s Administration Greater Los Angeles Healthcare System, Los Angeles, California, USA
Clin Gastroenterol Hepatol 7:168-74, 174.e1. 2009..We performed a national vignette survey to measure variations in decision-making in areas of controversy... - Management of the pregnant IBD patientMarla Dubinsky
Department of Pediatrics, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Inflamm Bowel Dis 14:1736-50. 2008..We would like to emphasize that the information presented here must be individualized to the specific situation of each patient, their acceptance of risk, and their degree of disease severity... - Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's diseaseDermot P B McGovern
Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Hum Mol Genet 19:3468-76. 2010..001). These findings strongly implicate this locus in CD susceptibility and highlight the role of the mucus layer in the development of CD... - Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitisAderet Okon
Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
Am Surg 71:821-6. 2005..03). The incidence of CP was significantly higher after IPAA in UC patients having thrombocytosis before surgery compared to UC patients having a normal platelet count before surgery... - A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosisPhillip Fleshner
Division of Colon and Rectal Surgery, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 5:952-8; quiz 887. 2007..The aim of this study was to identify important clinical risk factors associated with AP or CP... - Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammationThomas Hui
Division of Colon and Rectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
Dis Colon Rectum 48:1254-62. 2005.... - Genetic epistasis of IL23/IL17 pathway genes in Crohn's diseaseDermot P B McGovern
Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Inflamm Bowel Dis 15:883-9. 2009..Genetic variants in the IL23R and IL12B have been associated with CD susceptibility. We investigated 10 genes within the IL23/IL17 pathway in a case-control study of 763 CD cases and 254 healthy controls... - Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?Stefanie J Schluender
Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8737 Beverly Boulevard, Suite 101, Los Angeles, California 90048, USA
Dis Colon Rectum 50:1747-53. 2007..This study was designed to compare short-term complications in patients with ulcerative colitis who were treated with and without infliximab before colectomy... - Case report: evidence for transplacental transfer of maternally administered infliximab to the newbornEric A Vasiliauskas
Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Clin Gastroenterol Hepatol 4:1255-8. 2006..As a result of heightened maternal concern triggered by recent labeling changes, infliximab levels were measured in the newborn of a mother treated with infliximab... - Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprineMarla C Dubinsky
Department of Medicine, Division of Gastroenterology, Cedars-Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
Am J Gastroenterol 98:1058-63. 2003..Despite these favorable results, candidates for 6-TG should be selected with caution, and its use should be reserved for IBD patients well informed about potential toxicities... - Monitoring of AZA/6-MP treatment in children with IBD is necessaryMarla C Dubinsky
Pediatric Gastroenterology, Cedars-Sinai Hospital, Los Angeles, CA 90048, USA
Inflamm Bowel Dis 9:386-8; discussion 392-3. 2003 - Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapySunita Shastri
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Arch Pathol Lab Med 128:49-53. 2004..Reticulin-stained histologic sections are necessary to recognize this change. Further studies are needed to determine the frequency and significance of this change... - Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safetyMarla C Dubinsky
Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Clin Gastroenterol Hepatol 2:731-43. 2004..By gaining an understanding of the pharmacology and metabolism of thiopurine therapy and putting it into the clinical context, clinicians will be able to optimize thiopurine therapy in IBD... - Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of AmericaAthos Bousvaros
J Pediatr Gastroenterol Nutr 44:653-74. 2007..quot; The authors hope that progress being made in genetic, serological, and imaging studies leads to more reliable phenotyping... - Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel diseaseWilliam S Mow
Inflammatory Bowel Disease Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 2:31-40. 2004.... - A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurineMarla C Dubinsky
Department of Pediatrics, Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Am J Gastroenterol 100:2239-47. 2005.... - Suspected inflammatory bowel disease--the clinical and economic impact of competing diagnostic strategiesMarla C Dubinsky
Department of Pediatrics, Cedars Sinai-Medical Center, University of California Los Angeles School of Medicine, USA
Am J Gastroenterol 97:2333-42. 2002..The economic benefits seem to be achieved by avoiding invasive evaluations in patients without IBD. Confirmation of these findings in a prospective comparative trial seems to be warranted... - A pilot study of adalimumab in infliximab-allergic patientsAdrienne Youdim
Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
Inflamm Bowel Dis 10:333-8. 2004..Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab... - Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximabKonstantinos A Papadakis
Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, 8631 W. Third Street, Suite 430E, Los Angeles, CA 90048, USA
Am J Gastroenterol 100:75-9. 2005..CONCLUSIONS: Our preliminary data suggest that adalimumab may be a safe and effective therapy for patients with CD who have experienced an attenuated response to infliximab... - Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progressionMarla C Dubinsky
Department of Pediatrics, Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
Am J Gastroenterol 101:360-7. 2006.... - Challenges in pediatric inflammatory bowel diseaseAthos Bousvaros
Children s Hospital Boston and Harvard Medical School, Boston, MA 02115, USA
Inflamm Bowel Dis 12:885-913. 2006..At the conclusion of the meeting, investigators discussed the formation of a multicenter collaborative network to advance clinical and basic research in the field... - Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel diseaseStephen A Geller
Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Am J Surg Pathol 28:1204-11. 2004..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease... - Antibodies to I2 predict clinical response to fecal diversion in Crohn's diseaseJacob Spivak
Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Inflamm Bowel Dis 12:1122-30. 2006..CONCLUSION: Expression of I2 antibodies against a bacterial antigen of Pseudomonas fluorescens was highly associated with clinical response to fecal diversion in CD patients... - Disease perceptions among people with Crohn's diseaseSunanda V Kane
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Inflamm Bowel Dis 14:1097-101. 2008..We sought to characterize CD patient perceptions of both overall disease course and current symptomatology based on an objective symptom scale and to explore the relationship between perceptions and current symptoms... - Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how?Marla C Dubinsky
Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Rev Gastroenterol Disord 7:S3-7. 2007..Determining the factors that can predict the progression from uncomplicated to complicated disease states may stratify patients into at-risk populations and have an impact on their ultimate therapeutic management... - Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBDShane M Devlin
Inflammatory Bowel Disease Center, The University of Calgary, Calgary, Alberta, Canada
Inflamm Bowel Dis 14:125-8; discussion 132-3. 2008 - Severe colitis in childrenSubra Kugathasan
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
J Pediatr Gastroenterol Nutr 41:375-85. 2005
Research Grants
- The Natural History of Pediatric Crohn's DiseaseMarla Dubinsky; Fiscal Year: 2007..abstract_text> ..
- Parental Expression of Immune Responses In Pediatric Crohn's DiseaseMarla Dubinsky; Fiscal Year: 2007..The characterization of the potential risk milieu implied by the presence of immune responses at the sub clinical level in the child's' parents will offer new information on the influence of immune phenotypes on clinical outcomes. ..